Ignite Creation Date:
2024-05-05 @ 11:40 AM
Last Modification Date:
2024-10-26 @ 9:11 AM
Study NCT ID:
NCT00109122
Status:
COMPLETED
Last Update Posted:
2017-03-15
First Post:
2005-04-22
Brief Title:
Safety Tolerability and the Bodys Ability to Develop Resistance to an Investigational Vaccine for Shingles V211-007
Sponsor:
Merck Sharp Dohme LLC
Organization:
Merck Sharp Dohme LLC
Study Overview
Official Title:
A Double-Blind Placebo-Controled Randomized Study to Evaluate Safety Tolerability and Immunogenicity After 1 and 2 Doses of Zoster Vaccine
Status:
COMPLETED
Status Verified Date:
2017-03
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
The purpose of this study is to determine the immunity the bodys protection against shingles after receiving two doses of an investigational vaccine or placebo a look alike vaccine with no active ingredients
Detailed Description:
The duration of treatment is 12 weeks
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None
Secondary IDs
| Secondary ID | Type | Domain | Link |
|---|---|---|---|
| 2005_017 | None | None | None |